$AXSM
Axsome Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022022710 Filed on November 07, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $24.37M $16.85M $0.00
YoY Change
Cost Of Revenue $2.291M $1.900M
YoY Change
Gross Profit $22.08M $14.95M
YoY Change
Gross Profit Margin 90.6% 88.72%
Selling, General & Admin $61.50M $40.89M $20.23M
YoY Change 226.65% 102.17% 219.54%
% of Gross Profit 278.51% 273.61%
Research & Development $14.69M $14.88M $13.18M
YoY Change 6.61% 12.87% -10.92%
% of Gross Profit 66.54% 99.54%
Depreciation & Amortization $1.692M $1.607M $27.23K
YoY Change 5351.42% 5800.81% 172.3%
% of Gross Profit 7.66% 10.75%
Operating Expenses $82.00M $55.77M $33.41M
YoY Change 151.46% 66.94% 58.13%
Operating Profit -$59.92M -$42.41M -$33.41M
YoY Change 26.96% 58.13%
Interest Expense -$1.323M -$2.411M -$1.476M
YoY Change -3.32% 63.4% 168.28%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$61.24M -$44.82M -$34.88M
YoY Change 80.24% 28.5% 52.19%
Income Tax
% Of Pretax Income
Net Earnings -$61.24M -$44.82M -$34.88M
YoY Change 80.24% 28.5% 52.16%
Net Earnings / Revenue -251.28% -266.08%
Basic Earnings Per Share -$1.07 -$0.93
Diluted Earnings Per Share -$1.41 -$1.07 -$925.7K
COMMON SHARES
Basic Shares Outstanding 43.43M 41.70M 37.68M
Diluted Shares Outstanding 41.70M 37.68M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $200.8M $227.5M $114.6M
YoY Change 132.26% 98.49% -43.37%
Cash & Equivalents $200.8M $227.5M $114.6M
Short-Term Investments
Other Short-Term Assets $2.781M $2.458M $401.3K
YoY Change 6039.7% 512.39% -55.41%
Inventory $4.320M $2.103M
Prepaid Expenses
Receivables $37.70M $20.30M
Other Receivables $0.00 $0.00
Total Short-Term Assets $245.6M $252.4M $115.0M
YoY Change 183.92% 119.42% -43.41%
LONG-TERM ASSETS
Property, Plant & Equipment $722.5K $627.0K $314.9K
YoY Change 154.54% 99.11% 692.28%
Goodwill $10.31M $11.90M
YoY Change
Intangibles $59.66M $61.27M
YoY Change
Long-Term Investments
YoY Change
Other Assets $14.72M $12.40M $322.9K
YoY Change 4458.89% 3739.53% 1.74%
Total Long-Term Assets $85.83M $86.57M $1.574M
YoY Change 6675.08% 5399.13% 340.84%
TOTAL ASSETS
Total Short-Term Assets $245.6M $252.4M $115.0M
Total Long-Term Assets $85.83M $86.57M $1.574M
Total Assets $331.5M $339.0M $116.6M
YoY Change 277.6% 190.71% -42.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $38.61M $12.84M $13.38M
YoY Change 193.59% -4.01% 18.26%
Accrued Expenses $52.06M $40.44M $11.33M
YoY Change 424.97% 257.06% 25.84%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $96.56M $60.28M $24.71M
YoY Change 318.64% 143.99% 21.46%
LONG-TERM LIABILITIES
Long-Term Debt $94.26M $93.91M $49.17M
YoY Change 92.01% 90.98% 2.39%
Other Long-Term Liabilities $31.10M $27.40M $0.00
YoY Change
Total Long-Term Liabilities $94.26M $93.91M $49.17M
YoY Change 92.01% 90.98% 2.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $96.56M $60.28M $24.71M
Total Long-Term Liabilities $94.26M $93.91M $49.17M
Total Liabilities $221.9M $181.6M $73.88M
YoY Change 207.56% 145.8% 8.06%
SHAREHOLDERS EQUITY
Retained Earnings -$596.3M -$535.1M -$375.2M
YoY Change 45.72% 42.62% 50.32%
Common Stock $705.9M $692.5M $417.9M
YoY Change 66.16% 65.68% 11195742.3%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $109.6M $157.4M $42.72M
YoY Change
Total Liabilities & Shareholders Equity $331.5M $339.0M $116.6M
YoY Change 277.6% 190.71% -42.74%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$61.24M -$44.82M -$34.88M
YoY Change 80.24% 28.5% 52.16%
Depreciation, Depletion And Amortization $1.692M $1.607M $27.23K
YoY Change 5351.42% 5800.81% 172.3%
Cash From Operating Activities -$27.56M -$22.76M -$26.78M
YoY Change -4.43% -15.01% 70.22%
INVESTING ACTIVITIES
Capital Expenditures $180.9K -$66.05K -$258.7K
YoY Change -74.47% 1193.4%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$180.9K -$66.05K -$258.7K
YoY Change -74.47% 1193.4%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.066M 176.9M 438.7K
YoY Change 54.36% 40236.82% -98.4%
NET CHANGE
Cash From Operating Activities -27.56M -22.76M -26.78M
Cash From Investing Activities -180.9K -66.05K -258.7K
Cash From Financing Activities 1.066M 176.9M 438.7K
Net Change In Cash -26.68M 154.1M -26.60M
YoY Change -5.23% -679.5% -327.9%
FREE CASH FLOW
Cash From Operating Activities -$27.56M -$22.76M -$26.78M
Capital Expenditures $180.9K -$66.05K -$258.7K
Free Cash Flow -$27.74M -$22.69M -$26.52M
YoY Change -3.8% -14.43% 68.79%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q3 us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
CY2022Q3 us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001579428
us-gaap Type Of Cost Good Or Service Extensible List
TypeOfCostGoodOrServiceExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Amendment Flag
AmendmentFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Type Of Revenue Extensible List
TypeOfRevenueExtensibleList
http://fasb.org/us-gaap/2022#ProductMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37635
dei Entity Registrant Name
EntityRegistrantName
AXSOME THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
45-4241907
dei Entity Address Address Line1
EntityAddressAddressLine1
22 Cortlandt Street
dei Entity Address Address Line2
EntityAddressAddressLine2
16th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10007
dei City Area Code
CityAreaCode
212
dei Local Phone Number
LocalPhoneNumber
332-3241
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
dei Security12b Title
Security12bTitle
Common Stock, Par Value $0.0001 Per Share
dei Trading Symbol
TradingSymbol
AXSM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43426162
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
2906667
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
20302222
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.57
CY2022Q3 us-gaap Inventory Net
InventoryNet
2103477
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2457513
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
45286
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14877021
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
13180258
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
43254364
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44279272
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40892443
us-gaap Revenues
Revenues
0
CY2022Q3 us-gaap Assets Current
AssetsCurrent
252383430
CY2021Q4 us-gaap Assets Current
AssetsCurrent
86518140
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
20226884
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
97756314
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
47819618
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
626990
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
283846
CY2022Q3 axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
-42120
axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
-902120
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1606789
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2532439
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
59257964
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
384568
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
660162
CY2022Q3 us-gaap Goodwill
Goodwill
11897000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
61267561
CY2022Q3 us-gaap Other Inventory Noncurrent
OtherInventoryNoncurrent
12398220
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
33407142
us-gaap Costs And Expenses
CostsAndExpenses
145547664
us-gaap Costs And Expenses
CostsAndExpenses
92098890
CY2021Q4 us-gaap Other Inventory Noncurrent
OtherInventoryNoncurrent
322910
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-42412172
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-33407142
CY2022Q3 us-gaap Assets
Assets
338957769
CY2021Q4 us-gaap Assets
Assets
87785058
us-gaap Operating Income Loss
OperatingIncomeLoss
-119882086
us-gaap Operating Income Loss
OperatingIncomeLoss
-92098890
CY2022Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-2411040
CY2021Q3 us-gaap Investment Income Net
InvestmentIncomeNet
-1475535
us-gaap Investment Income Net
InvestmentIncomeNet
-6011953
us-gaap Investment Income Net
InvestmentIncomeNet
-4327966
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-44823212
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-34882677
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
12844629
us-gaap Net Income Loss
NetIncomeLoss
-125894039
us-gaap Net Income Loss
NetIncomeLoss
-96426856
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13149329
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
40021759
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
87785058
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16845792
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9295180
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
416876
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
620675
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
7000000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
60283264
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
23065184
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
27400000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
93913159
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49089522
CY2022Q3 us-gaap Liabilities
Liabilities
181596423
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.57
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
25665578
CY2022Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
1923831
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43425707
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43425707
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37816794
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37816794
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4342
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3782
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
692450128
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
227520218
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
86472854
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
424825655
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-535093124
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-409199085
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
157361346
CY2021Q4 us-gaap Liabilities
Liabilities
72154706
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15630352
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
338957769
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41704362
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41704362
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37680966
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37680966
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39715261
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39715261
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37569416
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37569416
CY2022Q3 axsm Stock Vested During Period Value Restricted Common Stock Award
StockVestedDuringPeriodValueRestrictedCommonStockAward
1
CY2022Q3 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
174984808
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
113792909
CY2022Q3 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
261635
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-44823212
axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
-902120
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
157361346
us-gaap Profit Loss
ProfitLoss
-125894039
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3731097
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1913299
CY2021Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
6115864
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-29259970
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
96293199
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5456242
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
958895
CY2021Q2 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
1096503
CY2021Q2 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
84010
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-32284209
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
71436620
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5725217
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
438683
CY2021Q3 axsm Stock Vested During Period Value Restricted Common Stock Award
StockVestedDuringPeriodValueRestrictedCommonStockAward
1
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-34882677
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
42717844
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
15630352
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7598329
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
181637
CY2022Q1 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
31008601
CY2022Q1 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
88594
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-39632311
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
14698014
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10161678
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
176412
CY2022Q2 axsm Stock Issued During Period Value Financing
StockIssuedDuringPeriodValueFinancing
30794647
CY2022Q2 axsm Warrants Issued During Period Debt Financing
WarrantsIssuedDuringPeriodDebtFinancing
826153
CY2022Q2 axsm Adjustments To Additional Paid In Capital Shares Tendered For Withholding Taxes
AdjustmentsToAdditionalPaidInCapitalSharesTenderedForWithholdingTaxes
18926
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-41438516
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
15199462
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9197661
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3064261
us-gaap Profit Loss
ProfitLoss
-96426856
us-gaap Share Based Compensation
ShareBasedCompensation
26957668
us-gaap Share Based Compensation
ShareBasedCompensation
14912556
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2532439
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1136951
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
851862
us-gaap Depreciation
Depreciation
178107
us-gaap Depreciation
Depreciation
45305
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
836974
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
802949
axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-765179
axsm Change In Operating Lease Liability
ChangeInOperatingLeaseLiability
-922179
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
20302222
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
8600
axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
2412227
axsm Increase Decrease In Prepaid Expense And Other Assets Current
IncreaseDecreaseInPrepaidExpenseAndOtherAssetsCurrent
252929
axsm Non Current Inventory And Other Assets
NonCurrentInventoryAndOtherAssets
727187
axsm Non Current Inventory And Other Assets
NonCurrentInventoryAndOtherAssets
5535
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-304700
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-122341
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
30726579
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
1731923
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-88947556
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-79385245
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
521251
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
307549
us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
53000000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-53521251
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-307549
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
45000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
487160
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
236788056
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7212367
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3422310
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3310877
axsm Payment Of Contingent Consideration
PaymentOfContingentConsideration
-837880
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
369155
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
84010
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
283516171
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10439234
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
141047364
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-69253560
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
86472854
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
183876453
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
227520218
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114622893
us-gaap Interest Paid Net
InterestPaidNet
5116806
us-gaap Interest Paid Net
InterestPaidNet
3482083
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
561380
axsm Fair Value Of Contingent Consideration In A Business Combination
FairValueOfContingentConsiderationInABusinessCombination
34400000
CY2022Q3 axsm Number Of Not Yet Approved Product Candidates
NumberOfNotYetApprovedProductCandidates
3
CY2022Q3 axsm Number Of Approved Products
NumberOfApprovedProducts
2
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-535100000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Management considers many factors in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements if these results differ from historical experience, or other assumptions do not turn out to be substantially accurate, even if such assumptions are reasonable when made. In preparing these financial statements, management used significant estimates in the following areas, among others: stock‑based compensation expense; the determination of the fair value of the warrants; the accounting for research and development costs; accounting for acquisitions; impairments goodwill and intangible assets; contingent consideration; chargebacks, cash discounts, sales rebates, returns and other adjustments; and the recoverability of the Company’s net deferred tax assets and related valuation allowance.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
227500000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash. The Company maintains its cash at financial institutions, which at times, exceed federally insured limits. At September 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">, the majority of the Company’s cash was held by </span><span style="font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> financial institution and the amount on deposit was in excess of Federal Deposit Insurance Corporation insurance limits. The Company has not recognized any losses from credit risks on such accounts since inception. The Company believes it is not exposed to significant credit risk on cash. At the time of contract inception or customer account set-up, the Company performs a collectability assessment on the creditworthiness of such customer. In 2022, all of the Company’s accounts receivable arose from product sales in the U.S. and all customers have standard payment terms. The Company’s accounts receivable balance as of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">September 30, 2022</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> is compromised solely from transactions with the Company’s 3PL.</span></p>
CY2022Q3 axsm Number Of Financial Institutions Holding Deposits
NumberOfFinancialInstitutionsHoldingDeposits
1
us-gaap Number Of Reporting Units
NumberOfReportingUnits
1
CY2022Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
1900000
us-gaap Cost Of Revenue
CostOfRevenue
2900000
CY2021Q3 us-gaap Revenues
Revenues
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
11897000
CY2022Q3 us-gaap Goodwill
Goodwill
11897000
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
63800000
us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2532439
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
61267561
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1606789
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
6374760
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
6392226
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
6374760
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
6374760
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
34144266
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
61267561
axsm Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Initial Estimate
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityInitialEstimate
36140000
axsm Change In Fair Value Of Contingent Considerations
ChangeInFairValueOfContingentConsiderations
-902120
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-837880
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
34400000
CY2022Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
2148471
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
9972575
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1867054
CY2022Q3 us-gaap Inventory Gross
InventoryGross
13988100
CY2022Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
0
CY2022Q3 us-gaap Inventory Net
InventoryNet
2103477
CY2022Q3 us-gaap Inventory Noncurrent
InventoryNoncurrent
11884623
CY2022Q3 us-gaap Inventory Gross
InventoryGross
13988100
CY2022Q3 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
4879849
CY2021Q4 axsm Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
2416897
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5632645
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4050236
CY2022Q3 axsm Accrued Selling General And Administrative Current
AccruedSellingGeneralAndAdministrativeCurrent
12856390
CY2021Q4 axsm Accrued Selling General And Administrative Current
AccruedSellingGeneralAndAdministrativeCurrent
2442700
CY2022Q3 us-gaap Accrued Sales Commission Current
AccruedSalesCommissionCurrent
14458129
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1347663
CY2022Q3 us-gaap Interest Payable Current
InterestPayableCurrent
847083
CY2021Q4 us-gaap Interest Payable Current
InterestPayableCurrent
385347
CY2022Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
40021759
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
9295180
CY2022Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
2579910
CY2021Q3 us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
1169167
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
5578542
us-gaap Interest Expense Debt Excluding Amortization
InterestExpenseDebtExcludingAmortization
3469375
CY2022Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
203656
CY2021Q3 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
155226
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
461695
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
448096
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
95000000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
50000000
CY2022Q3 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
1156377
CY2021Q4 axsm Debt Instrument Accreted Liability Of Final Payment Fee
DebtInstrumentAccretedLiabilityOfFinalPaymentFee
706407
CY2022Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
2243218
CY2021Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
1616885
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
93913159
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
49089522
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
15202884
CY2022Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
79797116
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
95000000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-44823212
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-34882677
us-gaap Net Income Loss
NetIncomeLoss
-125894039
us-gaap Net Income Loss
NetIncomeLoss
-96426856
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
41704362
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41704362
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37680966
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37680966
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
39715261
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39715261
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
37569416
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37569416
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.17
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.57
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7282612
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4912384
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
315000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
105000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
420000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
3124
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
416876
us-gaap Lessee Operating Lease Description
LesseeOperatingLeaseDescription
In August 2022, the Company entered into an agreement to extend the lease of 22 Cortlandt Street through April 30, 2023.
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
extend the lease of 22 Cortlandt Street through April 30, 2023.
CY2022Q1 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y7M6D
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.060
axsm Equity Instrument Voting Rights Per Share
EquityInstrumentVotingRightsPerShare
1
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5090377
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
28.89
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2039978
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
37.03
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
271371
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
12.68
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
288929
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
40.00
axsm Share Based Compensation Arrangement By Share Based Payment Award Options Expired In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
25172
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
49.22
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6544883
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
31.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
117059731
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
6544883
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
31.26
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y6M
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
117059731
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3184788
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.99
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y9M18D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
88486468
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
28.07
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
97700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y1M6D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
6169
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
9197661
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5725217
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
26957668
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
14912556
CY2021Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
15541
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
80.43
axsm Warrants Issued In Period
WarrantsIssuedInPeriod
35255
axsm Warrants Issued In Period Weighted Average Exercise Price
WarrantsIssuedInPeriodWeightedAverageExercisePrice
31.91
axsm Warrants Exercised In Period
WarrantsExercisedInPeriod
0
axsm Warrants Exercised In Period Weighted Average Exercise Price
WarrantsExercisedInPeriodWeightedAverageExercisePrice
0
CY2022Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
50796
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
46.75

Files In Submission

Name View Source Status
0000950170-22-022710-index-headers.html Edgar Link pending
0000950170-22-022710-index.html Edgar Link pending
0000950170-22-022710.txt Edgar Link pending
0000950170-22-022710-xbrl.zip Edgar Link pending
axsm-20220930.htm Edgar Link pending
axsm-20220930.xsd Edgar Link pending
axsm-ex31_1.htm Edgar Link pending
axsm-ex31_2.htm Edgar Link pending
axsm-ex32_1.htm Edgar Link pending
axsm-ex32_2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
axsm-20220930_cal.xml Edgar Link unprocessable
axsm-20220930_def.xml Edgar Link unprocessable
axsm-20220930_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
axsm-20220930_pre.xml Edgar Link unprocessable
axsm-20220930_htm.xml Edgar Link completed
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending